GlobalData on MSN13d
Eisai and Biogen’s subcutaneous Leqembi set for FDA review
Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment ...
pharmaphorum13d
FDA sets August date for subcutaneous Leqembi decision
To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...
Yahoo Finance1mon
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
The administration of rHuPH20 increases the dispersion and absorption of immunoglobulin (IG) in the subcutaneous tissue, allowing larger volumes to be infused in the infusion site. This allows for ...
Cure Today7d
The Significance of the Subcutaneous Opdivo FDA Approval in Solid Tumors
Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means ...
Cure Today3d
How Subcutaneous vs IV May Affect Treatment Adherence in Cancer Care
Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version ...
Yahoo Finance13d
Eisai and Biogen’s subcutaneous Leqembi set for FDA review
The agency has set a Prescription Drug User Fee Act ... along with reducing visits to hospital or infusion sites. The subcutaneous autoinjector dosing, which would also take far less time than ...
Financial Post1mon
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
The administration of rHuPH20 increases the dispersion and absorption of immunoglobulin (IG) in the subcutaneous tissue, allowing larger volumes to be infused in the infusion site. This allows for ...